{"disease":{"id":"staining-method","name":"Staining method","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"brilliant-blue-g","indication_name":"Staining method","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tissueblue","generic_name":"BRILLIANT BLUE G","company_name":"Dutch Ophthalmic","drug_phase":"marketed","molecular_target":"P2X purinoceptor 7","drug_class":"Disclosing Agent [EPC]","quality_score":48,"revenue":null,"mechanism":"Tissueblue works by binding to the P2X purinoceptor 7, a specific receptor on cells, to reveal or stain tissues."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}